Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma

Shen, Aidong; Zhang, Yunqing; Yang, Huiling; Xu, Ruirong; Huang, Guowei

doi:10.1002/jso.23012

Cited by 71 publications

(51 citation statements)

References 39 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In OS, ZEB1 was revealed to be upregulated in patients with lung metastases compared with patients without lung metastases. In addition, the expression of ZEB1 in OS tissues was increased with increasing Enneking stage (38). These results indicated that ZEB1 may contribute to OS metastasis.…”

Section: Discussionmentioning

confidence: 67%

MicroRNA-150 functions as an antioncogenic regulator in osteosarcoma

Wang

Liao

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Numerous studies have demonstrated that microRNAs (miRs) are involved in several physiological and pathological processes, and participate in cancer initiation and progression. The abnormal expression of miR-150 has been reported in numerous types of human cancer. However, at present there are no studies of miR-150 in osteosarcoma (OS). Reverse transcription-quantitative polymerase chain reaction was performed to measure miR-150 expression levels in OS tissues and cell lines. Subsequent to transfection with miR-150 mimics or zinc finger E-box binding homeobox 1 (ZEB1) small interfering RNA, an MTT assay, Transwell migration and invasion assays, western blotting and a Dual-Luciferase reporter assay were performed in human OS cell lines. The present study revealed that miR-150 was downregulated in OS tissues and cell lines. In addition, the expression levels of miR-150 were correlated with the clinical stage and degree of distant metastasis of patients with OS. In addition, ZEB1 was identified as a direct target of miR-150 in vitro. In conclusion, miR-150 targeted ZEB1 to function as an antioncogenic regulator in OS. These findings elucidated a novel underlying mechanism for the pathogenic process in OS carcinogenesis and progression, and may provide novel targeted therapeutic regimens for patients with OS.

show abstract

Section: Discussionmentioning

confidence: 67%

MicroRNA-150 functions as an antioncogenic regulator in osteosarcoma

Wang

Liao

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…5,[40][41][42] Due to the pivotal role of ZEB1 in the downregulation of E-cadherin, ZEB1 acts as a driver of EMT and cancer progression. 16,28,33,34,44 Aberrant expression of ZEB1 has been observed in many human cancers, such as uterine cancer, 45 pancreatic cancer, 29,46 osteosarcoma, 47 lung cancer, 48,49 liver cancer, 50 gastric cancer, 51,52 colon cancer 53 and breast cancer. 30 In these tumors, ZEB1 expression correlates with loss of E-cadherin and is associated with advanced diseases or metastasis, which indicates the relevance of ZEB1 induction of EMT and tumor progression in clinical cancers.…”

Section: Zeb1 In Tumor Progressionmentioning

confidence: 99%

ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance

Zhang¹,

2015

View full text Add to dashboard Cite

Zinc finger E-box binding homeobox 1 (ZEB1) is a transcription factor that promotes tumor invasion and metastasis by inducing epithelial-mesenchymal transition (EMT) in carcinoma cells. EMT not only plays an important role in embryonic development and malignant progression, but is also implicated in cancer therapy resistance. It has been hypothesized that carcinoma cells that have undergone EMT acquire cancer stem cell properties including selfrenewal, chemoresistance and radioresistance. However, our recent data indicate that ZEB1 regulates radioresistance in breast cancer cells through an EMT-independent mechanism. In this Perspective, we review different mechanisms by which ZEB1 regulates tumor progression and treatment resistance. Based on studies by us and others, we propose that it is specific EMT inducers like ZEB1, but not the epithelial or mesenchymal state itself, that dictate cancer stem cell properties.

show abstract

“…Ras also drives sarcoma formation, and ZEB1 expression is linked to invasion and metastasis in these tumors, where epithelial-to-mesenchymal transition would not appear to be a factor. Taken together, these findings raise the possibility that ZEB1 may have roles in tumor progression extending beyond the ZEB1/miR-200 loop thought to facilitate invasion and metastasis (21)(22)(23)(24)(25).…”

mentioning

confidence: 92%

Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and Then Ras Proteins Are Required for Tumor Initiation and Progression

Liu

Sánchez-Tilló

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Ras mutation drives tumor initiation as well as invasion. Results: The ZEB1 transcription factor is sequentially induced with mutation of Rb1 and Ras, and these inductions are required for Ras-mediated tumor initiation and then invasion. Conclusion: ZEB1 plays a critical role in initiation and progression of Ras-mediated tumors. Significance: Induction ZEB1 is important for tumor initiation and invasion in a model of Ras-initiated cancer.

show abstract

Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma

Abstract: The overexpression of ZEB1 in osteosarcoma may be related to the carcinogenesis and development as well as metastasis and invasion of osteosarcoma.

Cited by 71 publications

References 39 publications

MicroRNA-150 functions as an antioncogenic regulator in osteosarcoma

MicroRNA-150 functions as an antioncogenic regulator in osteosarcoma

ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance

Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and Then Ras Proteins Are Required for Tumor Initiation and Progression

Contact Info

Product

Resources

About